ment, stem cell transplantation is increasingly being used in younger patients with poor prognosis CLL. [2] [3] [4] [5] Autologous stem cell transplantation in patients with CLL has been Autologous PBPC transplantation is a potentially curative treatment for patients with chronic lymphocytic hampered by two major obstacles. First, most patients are older, which makes myeloablative radiochemotherapy with leukemia (CLL). As the autografts are frequently contaminated with large numbers of tumor cells, we have prolonged cytopenias, as usually seen after autologous bone marrow transplantation (BMT), particularly difficult. Using studied double purging of PBPC using immunomagnetic CD34 ؉ cell selection (Isolex 300i) followed by negative peripheral blood progenitor cells (PBPC) instead of BM promises to reduce this complication. 6 Second, stem cell depletion with anti-CD19/20/23/37-labeled immunomagnetic beads. In four small-scale experiments using PBPC grafts from patients with CLL are frequently contaminated with large amounts of leukemic cells, which raises the from patients with CLL or leukemic low-grade lymphoma, double purging resulted in CD34
CLL, the use of unpurged grafts appears to be associated with considerable risks in patients with this disease. Moreenrichment from 1.6% (0.7-5.6) to 98.5% (96-99.8).
The CD34
؉ yield after double purging was 1.3-over, the Dana-Farber group 4 reported that relapses after ABMT for CLL occurred exclusively in patients whose 6.3 ؋ 10 6 /kg, according to a median recovery of 32%. The overall reduction of lymphoma cells was 5.6 (Ͼ4.6-autografts showed molecular evidence of tumor cell contamination after purging. Thus, purging has been performed 6) log. Although CLL cells were completely absent after purging in five cases as assessed by FACS, all grafts in the vast majority of autotransplants performed in patients with CLL to date. remained PCR positive. The first two patients have been reinfused with double selected products after myeloablAt present, immunomagnetic selection of CD34 + cells appears to be one of the most efficient methods of depletion ative radiochemotherapy and showed prompt and uneventful hematopoietic engraftment. We conclude of unwanted cells from PBPC grafts, resulting in a reduction of B cells of approximately 3 log. 10 Probably due that without significant loss of CD34 ؉ cells, negative depletion adds 2 log of CLL cell depletion to CD34 ؉ to the high contamination with leukemic cells prior to purging, however, most stem cell grafts from patients with CLL selection, resulting in an overall purging efficacy of more than 5 log. This combination of positive and negaremain PCR-positive after conventional CD34 + selection, whereas in the majority of follicular lymphomas PCR negative selection can be successfully applied even to heavily contaminated PBPC grafts.
tivity can be achieved. 5, 11 Thus, more vigorous methods of B cell depletion are required for CLL. Another uncertainty Keywords: PBPC; CD34 + selection; CLL; purging associated with simple CD34 + selection is the fact that the existence of CLL cells expressing the CD34-antigen cannot be excluded, 12 implying that such 'tumor stem cells' might The life expectancy of patients with chronic lymphocytic be enriched by purification of CD34 + cells. leukemia (CLL) may be considerably reduced if the disease Based on these considerations, adding a negative is in an advanced stage or if adverse prognostic factors are depletion step to CD34 + selection appears to be an attractpresent. 1 Since CLL is not curable with conventional treative approach to increase the efficacy of B cell reduction, and, simultaneously, eliminate possible CD34-positive CLL cells. In the present report, we describe a novel selection 1, 13 ) in described elsewhere. 14 In brief, cells were treated with three patients, B in one patient, C in one patient. Written ammonium chloride lysis, incubated with antibodies, informed consent was obtained from each patient participatwashed and fixed with 1% formaldehyde. At least 50 000 ing in this study. Patients were treated according to a protoevents were acquired to a FACScan flow cytometer (Becton col approved by the institutional review board.
Dickinson, Heidelberg, Germany). Multidimensional evaluFour preclinical experiments were performed with small ations were done with Cellquest Software (Becton samples of CD34 + selected PBPC which were derived from Dickinson). The antibodies used for the purposes of this patients with leukemic low-grade lymphoma (B-CLL = 1; study were: 8G12-PE, (HPCA-2/CD34), HLe-1-FITC follicular lymphoma = 2; mantle cell lymphoma = 1) who (CD45), Leu-12-FITC (CD19), and Leu-1-PE (CD5) (all were scheduled for high-dose radiochemotherapy. These from Becton Dickinson). Due to the distinct clustering of patients had also given informed consent. , and melphalan 20 mg/m 2 day 3) followed by filgrastim (10 g/kg s.c. daily; Amgen, Munich, Germany).
14 Leukapheresis was commenced on day 19 or day 20 after PCR the start of Dexa-BEAM. The first collection product was stored overnight at 4°C, pooled with the next day's product, Analysis of CDR3 rearrangements was carried out by twoand subjected to purification with the Isolex 300i System step semi-nested PCR amplification using the oligonucleo-(Baxter Biotech, Immunotherapy Division, Irvine, CA, tide primers FR3A (5Ј-ACACG GC(C/T)(G/C)) GTATT USA). Immunoselected CD34 + cells were then mixed with ACTGT-3′) for the FR3IgH region, LJH (5′-TGAGG GMP-grade Dynabeads (Baxter Europe, Unterschleissheim, AGACG GTGAC C-3′) for the JH-external region, and Germany) which had been sensitized with a cocktail of VLJH (5′-GTGAC CAGGG TNCCT TGGCC CCAG-3′) GMP-grade CD19, CD20, CD23, and CD37 monoclonal for the JH-internal region as previously described. 15 PCR antibodies (Baxter Europe). After 30 min of incubation at analysis of the major break point region (MBR) of t(14;18) room temperature rosetted target cells were separated by was performed with primers P 28 (5′-GGTGA CAGG magnetic forces, and the B cell depletion step was repeated.
GTCCC TTGGC CCCAG-3′) for the JH-region, P27 (5′-The resulting CD34 + B − product was suspended in freezing GCAAT TCCGC ATTTA ATTCA TGGTA TTCAG GATmedium at a concentration of 5-20 × 10 6 /ml, aliquoted in at 3′) for bcl-2 MBR, and P3 (5′-CGTGG CCTGT TTCAAleast two portions and transfered into cryotubes. Additional 3′) for bcl-2 MBR. Amplified t(14;18) DNA was analyzed leukapheresis products containing at least 2 × 10 6 /kg in a 2% agarose gel stained with ethidium bromide and CD34 + cells were stored without manipulation as backup. photographed under UV illumination. CDR3 PCR products Purified cells and backup underwent programmed freezing were analyzed on a non-denaturating polyacrylamide gel and were cryopreserved in liquid nitrogen until the day (Clean Gel; Pharmacia, Freiburg, Germany). After electroof reinfusion.
phoresis, distinct bands could be demonstrated by silver For the small-scale experiments, 4-10 × 10 6 cells were staining. As determined by serial dilution experiments, taken from PBPC products after CD34
+ selection using the PCR allows detection of approximately one tumor cell in Isolex 300i, and subjected to negative B cell depletion as already described. 10 4 (CDR3) or 10 5 normal cells (t (14;18) ).
Results
particularly interesting for patients with B-CLL, whose PBPC collection products are often heavily contaminated with leukemic cells.
Preclinical runs
Probably due to nonspecific adhesion of B cells to the To establish the procedure of combined purging, smallbeads, some patients show only a poor reduction of the scale experiments were performed with samples of CD34 + CLL cell fraction after immunomagnetic CD34 + selection selected PBPC from four patients with leukemic low-grade (Figure 1c and Ref. 18). Thus, another basic advantage of lymphoma. An excellent purity of CD34 + cells was already adding a negative step is to achieve sufficient purging also observed after CD34
+ selection (98%), which was further in these 'CD34 + dropouts'. Furthermore, combined increased to 99% after the negative step. The CD34 + cell positive/negative purging would eliminate possible CD19 + loss during positive and negative depletion was roughly one CD34 + cells ('tumor stem cells'), which might be enriched third of the initial content; the median overall recovery of by CD34 + selection alone.
CD34
+ cells was 34%. Due to the small numbers of tumor We chose B-CLL for evaluating this purging technique cells in the starting material, it was not possible to quantify because it is an important indication and because the high the reduction of tumor cells associated with the procedure.
numbers of tumor cells in the collection products facilitate Nevertheless, in one of four experiments leukemic cells quantification of the purging efficacy by flow cytometry. became undetectable after CD34
+ selection alone as As illustrated by the preclinical part of the study, the proassessed by FACS and PCR (t(14;18) = 2; CDR3 = 2). In cedure can be used similarly in other B cell neoplasias, the three remaining experiments, FACS and PCR negativity such as follicular lymphoma or mantle cell lymphoma. were achieved after the B cell depletion (Table 1) .
Apart from its excellent performance, this system appears particularly suitable for clinical use since it employs exclusively GMP-grade reagents. By replacing the B cell antiClinical runs bodies with appropriate T cell reagents, combined For clinical purposes, seven double selection runs were perpositive/negative selection may also be applied to alloformed with heavily contaminated PBPC grafts from five geneic PBPC grafts for purposes of T cell depletion. patients with B-CLL or lymphoplasmocytoid immunocyUnmanipulated PBPC collection products from healthy toma. The final purities and recoveries of CD34 + cells were donors contain T cell numbers similar to the range of Bcomparable to those observed in the preclinical studies, CLL cells in this study. Previous reports on T cell depletion although in the clinical setting the second step was associaof allogeneic PBPC suggest that additional measures are ted with a greater additional enrichment of CD34 + cells and required after conventional CD34 + selection to achieve a a much smaller cell loss; almost all of the nonspecific clinically sufficient reduction of T cell numbers.
19-22 Prereduction of CD34
+ cells occurred during the positive liminary studies involving CD4-and CD8-labeled Dynaselection step (Table 2) .
beads indicate that our double purging procedure might also With up to 75% of total MNC, the B cell contamination be useful in this context (unpublished observations). prior to purging was very high. CD34
+ selection resulted In spite of up to 6 log of tumor cell depletion, PCR negain a 3.6 log reduction of CD19 +
CD5
+ leukemic cells, and tivity of the clinical samples could never be achieved, the negative step added another 2 log, giving an overall implying that residual tumor cells are still present after doupurging efficacy of 5.6 log ( Table 3 ). In spite of this, ble purging. Based on the experience obtained in the preresidual tumor cells were detectable in the final product in clinical experiments, it appears to be advisable to minimize two of seven runs by FACS and in seven of seven runs by the number of tumor cells which are contained in the PBPC CDR3 PCR (Figures 1 and 2) . product prior to purging. In the present series, patients had To date, two patients have been reinfused with double up to 60 × 10 9 /l lymphocytes circulating in the peripheral selected products containing 6.7 and 2.9 × 10 6 /kg CD34 + blood at the start of mobilization chemotherapy. The cells, respectively, following myeloablative radiochemoresulting large tumor cell fractions in the collection protherapy. Prompt and uncomplicated engraftment occurred ducts are difficult to eradicate even with very effective in both patients with neutrophil recovery to 0.5 × 10 9 /l on purging strategies and -due to the increased sensitivity of days +8 and +10 and platelet recovery to 20 × 10 9 /l on days B-CLL cells to cell damage -tend to cause clotting prob-+12 and +11 post-transplant, respectively. lems during the selection procedure, leading to impaired CD34 + cell recovery and purity. In conclusion, in vivo depletion of circulating leukemic cells by appropriate cytoDiscussion toxic pretreatment should be performed prior to PBPC mobilization. Taken together, our data show that without significant The combined positive/negative purging procedure presented here can reproducibly deplete more than 5 logs loss of CD34 + cells, negative depletion can add about 2 log of CLL cell reduction to CD34 + selection, resulting in an of leukemic B cells from PBPC grafts without significantly affecting their hematopoietic capacity. This high purging overall purging efficacy of more than 5 log. This combination of positive and negative selection can be successefficacy is clearly superior to the results of B cell depletion strategies employing positive or negative selection alone.
fully applied even to heavily contaminated PBPC grafts at reasonable cost. However, the persistence of PCR-detectThese conventional methods are generally not able to eliminate more than 3 logs of tumor cells. 4, 10, 11, 16, 17 The excelable clonal CDR3 rearrangements after double selection suggests residual tumor cells in the final products. Therelent performance of our novel double purging technique is + selection, and after B cell depletion, respectively, in run 3A. Note the poor B cell depletion during the CD34 + selection step. fore, the number of circulating CLL cells should be minimized prior to PBPC mobilization to achieve optimum eradication of leukemic cells from the stem cell grafts. 1991; 325: 1525-1533.
